Rob Davis, Merck CEO (Jacquelyn Martin/AP Images)
May 31, 2024 03:53 PM EDT
Pharma

Mer­ck CEO says Keytru­da is ‘not a re­peat­able mod­el’

Kyle LaHucik

Senior Reporter

CHICA­GO — Can there be an­oth­er Keytru­da?

Mer­ck CEO Rob Davis, whose com­pa­ny makes the $25 bil­lion-a-year can­cer med­i­cine, says it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times